Multi-walled carbon nanotubes (MWCNT) are engineered nanomaterials widely used in industrial and biomedical applications. Yet, MWCNT inhalation may induce pulmonary adverse effects, and the MWCNT-7 (Mitsui-7) has been classified as possibly carcinogenic to humans. However, its molecular mechanisms of action are poorly understood and there are no biomarkers of exposure for occupational monitoring. Several pulmonary diseases, including lung cancer, have been associated with alterations in microRNA expression that are used as biomarkers of disease progression, and differentially-expressed microRNAs (DE miRNAs) can also allow understanding the molecular effects induced by a toxicant. In this study, we identify DE miRNAs in A549 alveolar epithelial cells following 24 h exposure to MWCNT-7 or crocidolite, as well as their enriched cellular functional pathways. These indicate that both materials change cell survival, differentiation and proliferative properties under the influence of AMPK, FoxO, TGF-β and Hippo pathways, and their metabolic activity and cell-to-cell communication. In addition, MWCNT-7 affects the actin cytoskeleton, ubiquitin mediated proteolysis, and ECM-receptor interactions; crocidolite the PI3K-Akt and mTOR pathways, endocytosis, and central carbon metabolism. Since deregulation of these pathways may be related to carcinogenesis, an interaction network of DE miRNAs and corresponding target cancer-related genes was constructed, highlighting the carcinogenic potential of Mitsui-7.

2019-12-11·Nanomaterials (Basel, Switzerland)3区 · 材料科学

Quantification of Carbon Nanotube Doses in Adherent Cell Culture Assays Using UV-VIS-NIR Spectroscopy.

3区 · 材料科学

ArticleOA

作者: Dedy Septiadi ; Laura Rodriguez-Lorenzo ; Sandor Balog ; Miguel Spuch-Calvar ; Giovanni Spiaggia ; Patricia Taladriz-Blanco ; Hana Barosova ; Savvina Chortarea ; Martin J D Clift ; Justin Teeguarden ; Monita Sharma ; Alke Petri-Fink ; Barbara Rothen-Rutishauser

The overt hazard of carbon nanotubes (CNTs) is often assessed using in vitro methods, but determining a dose-response relationship is still a challenge due to the analytical difficulty of quantifying the dose delivered to cells. An approach to accurately quantify CNT doses for submerged in vitro adherent cell culture systems using UV-VIS-near-infrared (NIR) spectroscopy is provided here. Two types of multi-walled CNTs (MWCNTs), Mitsui-7 and Nanocyl, which are dispersed in protein rich cell culture media, are studied as tested materials. Post 48 h of CNT incubation, the cellular fractions are subjected to microwave-assisted acid digestion/oxidation treatment, which eliminates biological matrix interference and improves CNT colloidal stability. The retrieved oxidized CNTs are analyzed and quantified using UV-VIS-NIR spectroscopy. In vitro imaging and quantification data in the presence of human lung epithelial cells (A549) confirm that up to 85% of Mitsui-7 and 48% for Nanocyl sediment interact (either through internalization or adherence) with cells during the 48 h of incubation. This finding is further confirmed using a sedimentation approach to estimate the delivered dose by measuring the depletion profile of the CNTs.

2008-06-01·Neurochemistry International3区 · 医学

Increase of monoamine oxidase-B activity in the brain of scrapie-infected hamsters

3区 · 医学

Article

作者: Adjou, Karim Tarik ; Dilda, Pierre ; Aumond, Pascal ; Gueddari, Salah ; Deslys, Jean-Philippe ; Dormont, Dominique ; Seman, Michel

In the present study, the purpose is to determine activities of monoamine oxidases (MAO) in the brain of 263K scrapie-infected hamsters during the development of this experimental prion disease. Indeed, MAO activity modifications which have already been related in aging and neurodegenerations is suspected to be involved in the neuron loss process by elevated hydrogen peroxide formation. Monoamine oxidase type A (MAO-A) and B (MAO-B) activities were followed in the brain at different stages of the disease. MAO-A activity did not change significantly during the evolution of the disease. However, concerning the MAO-B activity, a significant increase was observed from 50 days post-infection and through the course of the disease and reached 42.9+/-5.3% at its ultimate stage. Regarding these results, MAO-B could be a potential therapeutic target then we have performed a pre-clinical treatment with irreversible (Selegiline or L-deprenyl) or and reversible (MS-9510) MAO-B inhibitors used alone or in association with an anti-scrapie drug such as MS-8209, an amphotericin B derivative. Our results show that none of the MAO-B inhibitors used was able to delay the onset of the disease. Neither these MAO-B inhibitors nor R-NMDA inhibitors (MK-801) can enhance the effects of MS-8209. The present findings clearly indicate a significant increase of cerebral MAO-B activity in scrapie-infected hamsters. Furthermore, inhibitors of MAO-B do not have any curative or palliative effect on this experimental model indicating that the raise of this activity is probably more a consequence rather than a causal event of the neurodegenerative process.

项与 MS-8209 相关的新闻（医药）

2023-08-25

·PRNewswire

Analysis of the Global AI in Clinical Trials Industry, 2023 to 2035 - Product/Technology Utilization and Integration Agreements Lead the Way in Partnerships

DUBLIN, Aug. 25, 2023 /PRNewswire/ -- The "Global AI in Clinical Trials Market: Trends and Forecasts 2023-2035" report has been added to ResearchAndMarkets.com's offering. The global AI in clinical trials market is estimated to be worth $ 1.4 billion in 2023 and expected to grow at compounded annual growth rate (CAGR) of 16% during the forecast period. The process of successfully developing a novel therapeutic intervention is both time and cost intensive. In fact, it is estimated that a drug requires around 10 years and over $ 2.5 billion capital investment, before reaching the market. In this process, clinical trials play a crucial role for assessing the drug's efficacy and safety in humans. These trials account for nearly 50% of the time and capital expenditure during drug development. However, sponsors face financial burdens and significant delays in marketing drugs due to unsuccessful clinical trials. Over the past few decades, the success rate of a drug candidate advancing the clinical trials to obtaining marketing approval has remained relatively constant at approximately 10% - 20%. This can be attributed to the factors contributing to clinical stage intervention failure, including inadequate study design, incomplete patient recruitment, improper subject stratification and high rate of clinical trial participant attrition. In order to overcome these challenges and streamline the clinical trial processes, stakeholders in the pharmaceutical industry are exploring innovative solutions and strategies. One such innovative strategy involves integrating AI in drug development, which has the potential to revolutionize traditional methods, particularly in clinical trials. It is worth noting that artificial intelligence in clinical trials can help integrate and analyze large volumes of data, enabling trial sponsors to optimize future research initiatives. Additionally, by addressing issues related to trial design, patient recruitment and retention, site selection, data interpretation, and treatment evaluation, AI has the potential to enhance and refine the entire process of clinical drug development. Moreover, in the first nine months of 2021, more than $20 billion was invested into artificial intelligence companies focused on healthcare, exceeding the prior investment, which was around $15 billion in 2020. Therefore, with the rising interest of investors in this field, we anticipate the AI in clinical trials market to witness healthy growth during the forecast period. Key Market Insights The report features an extensive study of the current market landscape, market size and future opportunities associated with the AI in clinical trials market, during the given forecast period. Further, the report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the AI in clinical trials market report are briefly discussed below. Benefits and Growing Demand for Artificial Intelligence Solutions for Patient Recruitment and Clinical Data Analysis AI solutions have emerged as a promising tool in the drug development process. These AI tools help companies improve the accuracy and efficiency of testing, accelerate drug development and optimize clinical trial outcomes. In addition, leveraging AI software in clinical trials helps increasing patient recruitment and retention, reduces trial time and cost, and provides more accurate clinical data analysis, personalized medicine, trial design and real-time patient monitoring. It is worth highlighting that the ability of AI to automate and streamline labor-intensive tasks, improve decision-making processes, and identify patterns and trends in complex datasets has garnered significant attention and interest from stakeholders in the pharmaceutical industry. In May 2023, US based Owkin received letter of support from the European Medicines Agency (EMA) for the use of proprietary deep learning models for oncology clinical trial analysis; the company believes that this can reduce the clinical trial failure rates in randomized clinical trial. Further several artificial intelligence companies have developed AI-powered platforms that optimize patient identification for clinical trials. Additionally, AI algorithms can be trained to analyze large amounts of data in electronic health records to identify eligible participants. Owing to these applications and recognition of the immense potential of AI by researchers and sponsors, the demand for AI clinical trials is likely to continue to grow and transform the landscape of drug development by improving patient outcomes in clinical trials. Current Market Landscape of AI in Clinical Trials: AI Software and Service Providers The AI in clinical trials market landscape features a mix of large, mid-sized and small companies. Currently, around 130 players have the required expertise to offer various software and services to streamline clinical studies. Notably, at present, around 80% of these AI in clinical trials software and service providers are focusing on leveraging machine learning and deep learning algorithms, as they minimize data-based errors by accessing various data points simultaneously. Recent developments in this field indicate that the artificial intelligence companies in clinical trials are upgrading their capabilities to accommodate the current and anticipated demand for these software and services. Partnership and Collaboration Trends in the AI in Clinical Trials Market In recent years, several artificial intelligence companies have inked partnerships related to AI in clinical trials domain with other industry / non-industry players. It is worth highlighting that, since 2018, a significant number of strategic partnerships have been inked in the AI in clinical trials industry. It is worth highlighting that product / technology utilization and integration agreements are the most common types of partnerships inked by stakeholders in the AI clinical trials field. Owing to several advantages of artificial intelligence in clinical trials, stakeholders are acquiring other industry players offering AI solutions / AI software for different clinical trial applications in order to expand their capabilities and build a comprehensive product / service portfolio. In February 2023, ZS acquired Trials.ai, an intelligent study design company, to enhance its end-to-end solutions to reimagine study design for its clients. In addition, several big pharma companies, such as Bristol Myers Squibb, GlaxoSmithKline (GSK), Johnson & Johnson, Merck, Pfizer and Roche, have also taken partnership initiatives related to AI in clinical trials, indicating the promise and benefits that AI technology holds in clinical trials. Key Trends in the AI in Clinical Trials Market In the past six years, around 600 completed / ongoing clinical trials utilized AI tools and technologies for evaluating drugs / therapies for different therapeutic areas, indicating the substantial efforts made by researchers engaged in this domain. Further, most of the clinical studies were designed for the purpose of diagnostics and treatment. It is worth noting that the University of California, the National Institute of Allergy and Infectious Diseases, and Mayo Clinic are among the most active sponsors of completed / ongoing clinical trials involving AI solutions. Rise in Investment in AI in Clinical Trials Market The heightened interest in the AI in clinical trials market can be validated by the fact that, in the last five years, close to $2.5 billion has been invested in companies engaged in providing AI software and services for clinical trials by several investors based across the globe. The majority of the funds have been raised through venture rounds, followed by seed financing rounds. In addition, several big pharma players, such as Bristol Myers Squibb, Merck, Novartis, Pfizer and Sanofi have also invested in AI software and service providers for clinical trials. In June 2021, Antidote Technologies raised $23 million to expand its digital patient engagement programs and clinical trial recruitment services. AI in Clinical Trials Market Size Driven by the rising demand for artificial intelligence in clinical trials, lucrative opportunities are expected to emerge for players offering AI technology for clinical studies. The global market for AI in clinical trials is anticipated to grow at a significant pace, with a CAGR of 16% during the forecast period. Among the therapeutic areas for which AI tools are leveraged in clinical trials, oncological disorders are most likely to adopt these AI solutions for streamlining processes, such as patient recruitment and retention, trial design, site selection, clinical data analysis, patient monitoring and personalized treatment. In terms of end-users, biotechnology and pharmaceutical companies are likely to hold the majority share (75%) of the AI in clinical trials market. Key Artificial Intelligence Companies Supporting Clinical Trials Examples of the key companies engaged in the AI in clinical trials domain (the complete list of players is available in the full report) include (in alphabetic order) Acclinate, AiCure, Aidar Health, Aitia, A.I. VALI, Ancora.ai, Antidote Technologies, Beacon Biosignals, BUDDI.AI, ConcertAI, Curify, Deep 6 AI, ICON, Innoplexus, Massive Bio, Median Technologies, Novadiscovery, Owkin, PHASTAR, SiteRx and Viz.ai. This market report also includes an easily searchable excel database of all the AI software / AI solutions and service providers for clinical trials worldwide. Scope of the Report The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments. The research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market, across different geographies. The opinions and insights presented in the report were influenced by discussions held with stakeholders in this industry. The report also features detailed transcripts of interviews held with various industry stakeholders: Danielle Ralic (Co-Founder, Chief Executive Officer and Chief Technology Officer, Ancora.ai) Wout Brusselaers (Founder and Chief Executive Officer, Deep 6 AI) Dimitrios Skaltsas (Co-Founder and Executive Director, Intelligencia) R. A. Bavasso (Founder and Chief Executive Officer, nQ Medical) Grazia Mohren (Head of Marketing), Michael Shipton (Chief Commercial Officer), Darcy Forman (Chief Delivery Officer), Troy Bryenton (Chief Technology Officer, Science 37) All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Key Topics Covered 1. PREFACE 1.1. Introduction 1.2. Key Market Insights 1.3. Scope of the Report 1.4. Research Methodology 1.5. Frequently Asked Questions 1.6. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Overview of Artificial Intelligence (AI) 3.3. Subfields of AI 3.4. Applications of AI in Healthcare 3.4.1. Drug Discovery 3.4.2. Drug Manufacturing 3.4.3. Marketing 3.4.4. Diagnosis and Treatment 3.4.5. Clinical Trials 3.5. Applications of AI in Clinical Trials 3.6. Challenges Associated with the Adoption of AI 3.7. Future Perspective 4. MARKET LANDSCAPE 4.1. Chapter Overview 4.2. AI in Clinical Trials: AI Software and Service Providers Landscape 4.2.1. Analysis by Year of Establishment 4.2.2. Analysis by Company Size 4.2.3. Analysis by Location of Headquarters 4.2.4. Analysis by Company Size and Location of Headquarters (Region) 4.2.5. Analysis by Key Offering(s) 4.2.6. Analysis by Business Model(s) 4.2.7. Analysis by Deployment Option(s) 4.2.8. Analysis by Type of AI Technology 4.2.9. Analysis by Application Area(s) 4.2.10. Analysis by Potential End-user(s) 5. COMPANY PROFILES 5.1. Chapter Overview 5.2. AiCure 5.3. Antidote Technologies 5.4. Deep 6 AI 5.5. Innoplexus 5.6. IQVIA 5.7. Median Technologies 5.8. Medidata 5.9. Mendel.ai 5.10. Phesi 5.11. Saama Technologies 5.12. Signant Health 5.13. Trials.ai 6. CLINICAL TRIAL ANALYSIS 6.1. Chapter Overview 6.2. Scope and Methodology 6.3. AI in Clinical Trials 6.3.1. Analysis by Trial Registration Year 6.3.2. Analysis by Number of Patients Enrolled 6.3.3. Analysis by Trial Phase 6.3.4. Analysis by Trial Status 6.3.5. Analysis by Trial Registration Year and Status 6.3.6. Analysis by Type of Sponsor 6.3.7. Analysis by Patient Gender 6.3.8. Analysis by Patient Age 6.3.9. Word Cloud Analysis: Emerging Focus Areas 6.3.10. Analysis by Target Therapeutic Area 6.3.11. Analysis by Study Design 6.3.12. Most Active Players: Analysis by Number of Clinical Trials 6.3.13. Analysis of Clinical Trials by Geography 6.3.14. Analysis of Clinical Trials by Geography and Trial Status 6.3.15. Analysis of Patients Enrolled by Geography and Trial Registration Year 6.3.16. Analysis of Patients Enrolled by Geography and Trial Status 7. PARTNERSHIPS AND COLLABORATIONS 7.1. Chapter Overview 7.2. Partnership Models 7.3. AI in Clinical Trials: List of Partnerships and Collaborations 7.3.1. Analysis by Year of Partnership 7.3.2. Analysis by Type of Partnership 7.3.3. Analysis by Year and Type of Partnership 7.3.4. Analysis by Application Area 7.3.5. Analysis by Target Therapeutic Area 7.3.6. Analysis by Type of Partner 7.3.7. Most Active Players: Analysis by Number of Partnerships 7.3.8. Analysis by Geography 8. FUNDING AND INVESTMENT ANALYSIS 8.1. Chapter Overview 8.2. Types of Funding 8.3. AI in Clinical Trials: List of Funding and Investments 8.3.1. Analysis by Year of Funding 8.3.2. Analysis by Amount Invested 8.3.3. Analysis by Type of Funding 8.3.4. Analysis by Type of Funding and Amount Invested 8.3.5. Most Active Players: Analysis by Amount Raised and Number of Funding Instances 8.3.6. Leading Investors: Analysis by Number of Funding Instances 8.3.7. Analysis of Amount Invested by Geography 8.3.8. Analysis of Number of Funding Instances by Geography 8.4. Concluding Remarks 9. BIG PHARMA INITIATIVES 9.1. Chapter Overview 9.2. Scope and Methodology 9.3. Analysis by Year of Initiative 9.4. Analysis by Type of Initiative 9.5. Analysis by Application Area of AI 9.6. Analysis by Target Therapeutic Area 9.7. Benchmarking Analysis: Big Pharma Players 10. AI IN CLINICAL TRIALS: USE CASES 10.1. Chapter Overview 10.2. Use Case 1: Collaboration between Roche and AiCure 10.3. Use Case 2: Collaboration between Takeda and AiCure 10.4. Use Case 3: Collaboration between Teva Pharmaceuticals and Intel 10.5. Use Case 4: Collaboration between Unnamed Pharmaceutical Company and Antidote 10.6. Use Case 5: Collaboration between Unnamed Pharmaceutical Company and Cognizant 10.7. Use Case 6: Collaboration between Cedars-Sinai Medical Center and Deep 6 AI 10.8. Use Case 7: Collaboration between GlaxoSmithKline (GSK) and PathAI 10.9. Use Case 8: Collaboration between Bristol Myers Squibb (BMS) and Concert AI 11. VALUE CREATION FRAMEWORK: A STRATEGIC GUIDE TO ADDRESS UNMET NEEDS IN CLINICAL TRIALS 11.1. Chapter Overview 11.2. Unmet Needs in Clinical Trials 11.3. Key Assumptions and Methodology 11.4. Key Tools / Technologies 11.4.1. Blockchain 11.4.2. Big Data Analytics 11.4.3. Real-world Evidence 11.4.4. Digital Twins 11.4.5. Cloud Computing 11.4.6. Internet of Things (IoT) 11.5. Trends in Research Activity 11.6. Trends in Intellectual Capital 11.7. Extent of Innovation versus Associated Risks 11.8. Results and Discussion 11.9. Summary 12. COST SAVING ANALYSIS 12.1. Chapter Overview 12.2. Key Assumptions and Methodology 12.3. Overall Cost Saving Potential of AI in Clinical Trials, 2023-2035 12.3.1. Cost Saving Potential in Phase I Clinical Trials, 2023-2035 12.3.2. Cost Saving Potential in Phase II Clinical Trials, 2023-2035 12.3.3. Cost Saving Potential in Phase III Clinical Trials, 2023-2035 12.3.4. Cost Saving Potential in Patient Recruitment, 2023-2035 12.3.5. Cost Saving Potential in Patient Retention, 2023-2035 12.3.6. Cost Saving Potential in Staffing and Administration, 2023-2035 12.3.7. Cost Saving Potential in Site Monitoring, 2023-2035 12.3.8. Cost Saving Potential in Source Data Verification, 2023-2035 12.3.9. Cost Saving Potential in Other Procedures, 2023-2035 13. MARKET SIZING AND OPPORTUNITY ANALYSIS 13.1. Chapter Overview 13.2. Forecast Methodology and Key Assumptions 13.3. Global AI in Clinical Trials Market, 2023-2035 13.3.1. AI in Clinical Trials Market: Distribution by Trial Phase, 2023 and 2035 13.3.2. AI in Clinical Trials Market: Distribution by Target Therapeutic Area, 2023 and 2035 13.3.3. AI in Clinical Trials Market: Distribution by End-user, 2023 and 2035 13.3.4. AI in Clinical Trials Market: Distribution by Key Geographical Regions, 2023 and 2035 14. CONCLUSION 15. EXECUTIVE INSIGHTS 16. APPENDIX I: TABULATED DATA 17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS Companies Mentioned AbbVie Accelmed Accenture Acclinate Actelion Pharmaceuticals Adara Ventures AG Mednet Agent Health A.I. VALI AiCure Aidar Health AITIA AKESOgen AKRN Scientific Consulting (acquired by NAMSAN) Alexandria Venture Investments Alira Health AliveCor AllianceBernstein Alliance for Clinical Trials in Oncology Allucent Alpha MD ALS Association Alter Venture Partners Amadeus Capital Partners Amber Specialty Pharmacy American Society of Clinical Oncology (ASCO) Amgen Amgen Ventures Amplify Ancora.ai Anthem Anthemis Exponential Ventures Antidote Technologies Aperio APEX Digital Health APEX Ventures Arondor Artificial Intelligence in Medicine (AIM) (a subsidiary of Inspirata) ArtiQ Arvinas Asahi Kasei Ascension Ventures Aspen Insights Assistance Publique Hopitaux de Paris AstraZeneca ATAI Life Sciences AV8 Ventures Avalanche Venture Capital Avident Health Avira Digital Aviva Ventures Avon Baird Capital Baron Davis Enterprises Beacon Biosignals BEPATIENT Beyond Celiac Big Pi Ventures Bioforum Biofourmis Bioinfogate (acquired by Clarivate) Biomatics Capital Biomedical Advanced Research and Development Authority (BARDA) Blue Heron Capital Boehringer Ingelheim Boehringer Ingelheim Venture Fund (BIVF) Bold Capital Partners Bolton NHS Foundation Trust BootstrapLabs Boreal Ventures Bpifrance Brainomix Brainpan Innvovations Bridge Biotherapeutics Bristol Myers Squibb (BMS) Brite Health Bronze Valley BUDDI.AI BullFrog AI Cambridge Cognition Canary Speech Carebox Carenity (acquired by EvidentIQ) Carle Health Carlyle Casdin Capital Cathay Innovation Cavendish Impact Foundation (CIF) Cedar Health Research Celgene CellCarta Central Ohio Primary Care Physicians (COPC) The Centre for Aging + Brain Health Innovation (CABHI ) Cerba Research Chainlink Charterhouse Capital Partners Chartline Capital Partners ChemAxon Children's Oncology Group (COG) Chimera Partners Cigna Ventures CIMS Global Citeline ( a subsidiary of Norstella) Clario Clarivate ClearPoint Investment Partners Clinerion Clinevo Technologies clinicalAI CliniOps Clinithink ClinScape ClinTex CMIC Group Cognizant Community Health Network ConcertAI Constant Companion Creadev Crestle.ai (acquired by Doc.ai) Crista Galli Ventures Cumulus Neuroscience Curenetics Curify.ai CVS Health Dassault Systemes DataON Datavant DCM Ventures DCVC Bio Debiopharm Decibel Therapeutics Declaration Partners Deep 6 AI Deep Lens (acquired by Paradigm) DeepTrial Defense Health Agency Dementia Discovery Fund (DDF) Department of Veteran Affairs Deutsche Investitions und Entwicklungsgesellschaft (DEG) DiA Imaging Analysis doc.ai (acquired by Sharecare) Dong-A Socio Holdings EBSCO Information Services Echo Health Ventures EDBI Edison Partners Eight Roads Ventures eimageglobal EIT Health Elliott Investment Management Entrepreneur First Epilepsy Study Consortium Ergomed Erlanger Health System ERYTECH Espresso Capital Eugene M. Lang Foundation European Commission European Investment Bank European Regional Development Fund (ERDF) Excelra Experimental Cancer Medicine Centre (ECMC) Experimind Faber fathom it group FinLab EOS VC Fund First Analysis Corporation First Trust Capital Partners Florida Cancer Affiliates Folklore Ventures Fosun RZ Capital GE Healthcare Genentech General Atlantic General Catalyst Genoa Ventures Genomenon Genpro Research GlaxoSmithKline (GSK) Global Alzheimer's Platform Foundation Gloucestershire Cancer Alliance (SWAG) Google GV (formerly Google Ventures) Greater Gift Grey Sky Venture Partners Grove Ventures GSR Ventures Guy's and St Thomas' NHS Foundation Trust H1 H2O.ai Halo Health Hambro Perks Healint Healthix HealthMatch HealthVerity Hematology-Oncology Associates of Central New York (HOA) Jiangsu Hengrui Pharmaceuticals Herefordshire and Worcestershire Health and Care NHS Trust Heritage Medical Group Highline Sciences HCLTech Horizon Therapeutics Human API IBM iClusion ICON IKJ Capital iLoF IMA Group IMNA Solutions ImpactAssets Inato Indegene iNDX.Ai Inflection Biosciences Innoplexus Innovaderm Innovatrix Capital Insight Partners Insilico Medicine Inspirata Inspire Intel Intel Capital (a subsidiary of Intel) Intelligencia.ai Intermountain Ventures Investissement Quebec Iowa First Capital Fund Iowa Innovation Acceleration Fund IQ Capital IQVIA IXICO Janssen Pharmaceuticals Jianke Johns Hopkins University Johnson & Johnson Karyopharm Therapeutics Keosys Khosla Ventures King's Health Partners Kinship Kleiner Perkins Kognitic Labcorp Lambda Therapeutic Research LaunchCapital Launch Therapeutics LBO France Leal Health Legit.Health LEO Pharma Leukemia & Lymphoma Society Lieber Institute for Brain Development Life Image (acquired by Intelerad Medical SystemsT ) LifeArc Lightship Linguamatics (a subsidiary of IQVIA) Liquid 2 Ventures LMK Clinical Research Consulting Lokavant (a subsidiary of Roivant Sciences) LSU Health New Orleans Lunar Ventures M12 (formerly known as Microsoft Ventures) Massachusetts General Hospital Massive Bio MassMutual Ventures Matrix Capital Management Matrix Partners Maverick Ventures Maxer Consulting Mayfield Fund Mayo Clinic Mayo Clinic Ventures (a subsidiary of Mayo Clinic) McKesson Ventures (a subsidiary of McKesson) Medable Median Technologies Medica Medical Research Network (MRN) Medidata Solutions mediri Medpace MEDSOFT Medtronic Memorial Sloan Kettering Cancer Center (MSK) Mendel.ai Menlo Ventures Merck Merck Global Health Innovation Fund (Merck GHI) (a subsidiary of Merck) Microsoft Millennium Technology Value Partners Mitsui Moderna MSD Global Health Innovation Fund (MGHIF) MTIP Mubadala Capital Nanox National Cancer Institute (NCI) National Institute of Allergy and Infectious Diseases (NIAID) National Institute of Mental Health (NIMH) National Minority Health Association (NMHA) NEC NEC OncoImmunity (a subsidiary of NEC) NeoGenomics NetraMark NeuroEndocrine Cancer Australia New Enterprise Associates New Leaf Venture Partners Nex Cubed Next Level Ventures nference NJF Capital Nor-Tech North American Science Associates (NAMSA) Northpond Ventures Nova Discovery Novartis Novoic Novotech nQ Medical Nucleai NuvoAir Oak HC/FT Obvious Ventures Ocala Oncology Octopus Ventures Olive Tree OMRON Healthcare OncoBay Clinical OncoSec Medical One Nucleus OneStudyTeam Openspace Ventures Opyl Oracle Otium Venture ?URA Health Overline Venture Capital Owkin Oxford Finance University of Oxford Innovation Fund (UOIF) P1vital P360 P3Life Paige AI Palisades Growth Capital Pancare Foundation Pangaea Data Paradigm Parexel Parkwalk Advisors Partech Passage AI Patchai (acquired by Alira Health) PathAI Patient iP PatientPoint PatienTrials Patiro Pear Therapeutics Pepgra Perceiv AI Perceptive Advisors Perthera.ai Pfizer Pfizer Ventures (a subsidiary of Pfizer) Pharmamodelling Phastar phaware Phesi physIQ Plug and Play Ventures Point72 Ventures Population Health Partners PPC (merged with Novotech) PRA Health Sciences Precipio Prime Capital Pritzker Group ProofPilot Propeller Health Protocols.io PWNHealth Qmetrics Technologies Qualcomm Ventures Quality Cancer Care Alliance Network (QCCA) Quibim Quiet Capital Qure.ai Qwince Radical Ventures RadMD (acquired by Medica Group) Raylytic re.Mind Capital RealTime Software Solutions Red Abbey Labs Reify Health Remarque Systems Renmin Hospital of Wuhan University Rev1 Ventures Revo Capital Revolution Growth Risklick Rittenhouse Ventures Roche Roivant Sciences Royal Philips Rural Vitality Fund Rymedi Saama Technologies San Raffaele Hospital Sanofi Sanofi Ventures (a subsidiary of Sanofi) Scale Ventures Science37 Scipher Medicine Self-Care Catalysts Semicrol sensedat Sensyne Health Sequoia India Serena and Fly Ventures ServiceNow Servier SGInnovate Shandong University Sierra Ventures Sigmasoft Signant Health Silicon Valley Bank (SVB) SimBioSys Singtel Innov8 SiteGround Capital SiteRx Sixth Street Small Business Innovation Research (SBIR) Smedvig Capital SoftBank Vision Fund Somerset Sopris Capital SOSV Sourcia Southern Oncology Specialists Sozo Ventures SpringRock Ventures Square Peg Square Peg Capital Stanford Angels Stratus SubjectWell Sway Ventures SyMetric Symphony Clinical Research (acquired by ICON) SymphonyAI Syneos Health Synetro Synexus System Applications and Products in Data Processing (SAP) T. Rowe Price Taliaz Talkdesk Tamarind Hill Fund Teal Ventures Tech Transfer UPV TEDCO's Seed Fund Tempus Tencent Holdings Tenthpin TeraRecon TFS Services The Angels' Forum ThoughtSphere THREAD Tiger Global Management Timberline Holding TissueTech Translational Drug Development (TD2) TransPerfect Life Sciences Trialbee Trials.ai (acquired by ZS Associates) TrialSense Tribeca Venture Partners TriNetX TT Capital Partners TTi Health Research & Economics U.S. Food and Drug Administration (FDA) U.S. Veteran's Affairs UCB Biopharma UK Future Fund Underscore Venture Capital UnityPoint Health Ventures University of California University of Pennsylvania University of Pittsburgh Unlearn.AI Vastrax VeriSIM VersaTrial Vertex Ventures Veterans Prostate Cancer Awareness (VPCa) VIDA Viroclinics-DDL (acquired by Cerba HealthCare) VirTrial Vivoryon Therapeutics Viz.ai WallachBeth Capital WCG Clinical Wefight Wiley Winterlight Labs Wittington Ventures Worldwide Clinical Trials WP Global Partners XpertPatient Zola Global Investors ZS Associates For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

并购临床2期

2023-06-29

·PRNewswire

Astellas Establishes Open Innovation Hub for Tumor Microenvironment Research with Cutting-Edge Spatial Biology, in Mitsui Fudosan's "MITSUI LINK-Lab KASHIWA-NO-HA 1"

TOKYO, June 29, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Mitsui Fudosan Co., Ltd. (TSE: 8801, President and CEO: Takashi Ueda, "Mitsui Fudosan") announced today that Astellas will establish a "TME imaging and interactive research for innovation (TME iLab)" open innovation hub in October, 2023 in "MITSUI LINK-Lab KASHIWA-NO-HA 1" (Kashiwa City, Chiba Prefecture, "the Lab") operated by Mitsui Fudosan. About TME iLab open innovation hub for research of tumor microenvironment The two companies will collaborate to maximize the benefits of the Kashiwa-no-ha area, which is located close to many leading Japanese cutting-edge medical facilities and academia, including National Cancer Center Japan, with the aim of gaining new insights about the tumor microenvironment, a challenge in refractory cancer, and generating innovations based on the knowledge gained. At TME iLab, we aim to generate innovation through discussion between internal and external researchers, including Dr. Akihiro Ohashi, a division head of Collaboration Research and Development at Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, who is engaged in research as a Principal Investigator (PI)* at Astellas under the cross-appointment system. Cutting-edge spatial information analyzers and machine learning technologies, such as the spatial molecular imager "CosMx SMI", the system for spatial omics analysis "Xenium" and the multifluorescent tissue profiler "Orion", of the US companies NanoString, 10x Genomics and RareCyte respectively, will be made available to researchers at the facility. Mitsui Fudosan will provide the "Mitsui Link Lab Open Innovation Support Program*2" to create a mechanism to attract many researchers to TME iLab, and provide research and business support and communication/networking support. In order to continue to discover innovative drugs, including anticancer drugs, it is essential to bring together cutting-edge science in multiple fields and combine it in research and development. Using these cutting-edge facilities, we will promote "defining characteristics of the tumor microenvironment in clinical specimens," "selecting biomarkers for effective therapies from clinical data," and "identification of candidate target molecules that will become new therapeutic targets." "We are pleased to reach an agreement with Mitsui Fudosan. In our new hub of open innovation, we are seeking a wide range of partners with innovative expertise and technologies in tumor microenvironment research," said Yoshitsugu Shitaka, Ph.D., Chief Scientific Officer (CScO), Astellas. "By combining Astellas' capabilities in drug discovery with the knowledge of partners, including academia and venture companies, we expect to accelerate anticancer drug research and create innovative drugs. Through these activities, we will also contribute to further growth of the ecosystem in Kashiwa-no-ha Smart City." "We sincerely welcome Astellas to establish a hub in Kashiwa-no-ha. In the Kashiwa-no-ha area, a smart city is being built through public-private-academic collaboration, and in the life science area, an ecosystem that generates innovation is being created through the formation of communities to support both cross-collaboration between academia and industry on medical and healthcare-related initiatives and the social implementation of research and development seeds," said Kazunori Yamashita, Executive Managing Officer, General Manager, Mitsui Fudosan. "In the life science area as well, the creation of an ecosystem that fosters innovation is progressing. We, too, will contribute to the development of TME iLab and industrial growth, including the creation of innovative drugs, by working to create a place for promoting innovation and building a community." [MITSUI LINK-Lab KASHIWA-NO-HA 1] Address: 6-6-2 Kashiwa-no-ha, Kashiwa City, Chiba Access: 3 minutes by bus from "Kashiwanoha-campus" Station on the Tsukuba Express line, 3 minutes on foot from "Mitsui Garden Hotel Kashiwa-no-ha Park Side Mae (Zeikan Kenshujo)" bus stop *1 Principal Investigator (PI): One of the research professions at Astellas *2 For more information about Mitsui Link Lab Open Innovation Support Program, please see the press release "New Service from Mitsui Lab & Office MITSUI LINK-Lab Open Innovation Support Program Launched Supporting life science companies, including consultation services for research and management, common equipment room, and store stocked with research consumables and reagents" issued on May 18, 2023. About Astellas Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at . About Mitsui Fudosan Mitsui Fudosan is a comprehensive real estate developer that strives to solve social issues and create new value through urban development. Kashiwa-no-ha Smart City is an intellectual cluster of Japan's leading academia and medical facilities. In addition to Mitsui Link-Lab Kashiwa-no-ha 1 and Mitsui Garden Hotel Kashiwa-no-ha Park Side, a hotel that supports cancer patients located on the grounds of the National Cancer Center Hospital East, a variety of other facilities, including offices, commercial facilities, and a mobility field, create a bustling atmosphere. Through public-private-academic collaboration, the Smart City is also actively engaged in verification experiments utilizing startup and university technologies. (Kashiwa-no-ha Smart City: ) Cautionary Notes (Astellas) In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice. SOURCE Astellas Pharma Inc.

2023-03-02

·GlobeNewswire-Health Care

Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID

BEDMINSTER, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology to maximize global clinical impact and patient access, announces that MAT2203, an oral LNC formulation of amphotericin B (AMB), will be featured in two oral presentations at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). The hybrid in-person and virtual Congress is being held April 15-18 in Copenhagen and the MAT2203 presentations will both take place on April 18. The two presentations are as follows: “All-oral lipid nanocrystal amphotericin B for cryptococcal meningitis: a phase II randomized trial” will be presented by David Boulware, MD, MPH, Professor of Medicine at the University of Minnesota and Principal Investigator for the Phase 2 EnACT trial evaluating MAT2203 in cryptococcal meningitis.“Calcaneal Rhodotorula mucilaginosa osteomyelitis treated with oral amphotericin B (MAT2203)” - Senior Author, Marisa H. Miceli, MD, Professor of Medicine, Specializing in Fungal Infections and Transplant Diseases, Division of Infectious Diseases, Internal Medicine, at the University of Michigan. “We are delighted that clinical evidence supporting the ability of MAT2203 to safely and effectively improve outcomes for patients suffering from potentially deadly fungal infections will be presented at this prestigious conference,” said Theresa Matkovits, PhD, Chief Development Officer of Matinas BioPharma. “The efficacy of amphotericin B is well established, but this fungicidal drug is typically administered selectively only to patients with severe disease because of its toxicity, which significantly limits its use. MAT2203 reduces systemic toxicity by directing amphotericin B to targeted cells at sites of infection, supporting a favorable safety profile relative to IV-administered AMB with the additional benefit of oral administration. The data to be presented at ECCMID, from both our EnACT Phase 2 trial and a compelling compassionate use case, support our strategy of developing the ideal antifungal agent for the treatment of a variety of invasive fungal infections while also potentially having a dramatic pharmacoeconomic impact on the cost of treating these deadly diseases. “Importantly, success with MAT2203 gives us confidence that our platform technology can be applied beyond small molecules to a multitude of treatment modalities that alter the genetic mechanisms that underlie disease, an area we view as the future of medicine,” added Dr. Matkovits. “We believe that our delivery platform holds promise for the targeted delivery of gene therapy, providing Matinas with the opportunity to develop robust internal and partnered drug development candidates.” About MAT2203Matina BioPharma is developing MAT2203 as a potential oral broad-spectrum treatment for invasive deadly fungal infections. Although amphotericin B is a fungicidal agent, it is currently only available through an intravenous route of administration, which is known to be associated with a number of significant safety issues such as renal toxicity and anemia due to very high circulating levels of amphotericin B. MAT2203 has the potential to overcome the significant limitations of the currently available amphotericin B products due to its targeted oral delivery, combining comparable fungicidal activity with targeted delivery resulting in a lower risk of toxicity and potentially creating the ideal antifungal agent for the treatment of invasive fungal infections. About ECCMID The European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) has become one of the most comprehensive and influential congresses in the field of infectious diseases and an exciting networking opportunity, bringing together more than 14,000 colleagues from all over the world. The scientific program is built by the ECCMID Programme Committee, an independent group of experts representing all disciplines related to clinical microbiology, infectious diseases, infection control and prevention, and public health. About Matinas BioPharmaMatinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology to maximize global clinical impact and patient access. The Company is developing its own internal portfolio of products as well as partnering with leading pharmaceutical companies to develop novel formulations that capitalize on the unique characteristics of the LNC platform. Preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the challenges in achieving safe and effective intracellular delivery for both small molecules and larger, more complex molecules such as mRNA, DNA plasmids, antisense oligonucleotides, and vaccines. The combination of a unique mechanism of action and flexibility with formulation and route of administration (including oral) positions Matinas’ LNC technology potentially to become the preferred next-generation intracellular drug delivery vehicle with distinct advantages over both lipid nanoparticles and viral vectors. For more information, please visit www.matinasbiopharma.com. Forward-looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to our business activities, our strategy and plans, our collaborations with National Resilience, Inc. and BioNTech SE, the potential of our LNC platform delivery technology, and the future development of its product candidates, the Company’s ability to identify and pursue development, licensing and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma’s product candidates are all in a development stage and are not available for sale or use. Investor Contact LHA Investor RelationsJody Cain Jcain@lhai.com310-691-7100

临床2期

100 项与 MS-8209 相关的药物交易

登录后查看更多信息

研发状态

适应症	最高研发状态	国家/地区	公司
HIV感染	无进展	日本更多	Mitsui Pharmaceuticals, Inc. 更多
克-亚综合征	无进展	日本更多	Mitsui Pharmaceuticals, Inc. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ISRCTN68133435 (Pubmed \| Clin Infect Dis)	N/A	隐球菌脑膜炎	-	Amphotericin B 0.7 mg/kg per day	衊鬱願網鬱積築繭範築(選膚網淵鹽顧蓋窪膚廠) = 夢鏇鑰壓衊糧顧壓艱膚膚網製膚鬱憲淵醖鏇膚 (築繭淵壓觸壓餘鑰選鹽 )	-	2008-07-01
				Amphotericin B 1 mg/kg per day	衊鬱願網鬱積築繭範築(選膚網淵鹽顧蓋窪膚廠) = 夢鏇廠淵夢鏇衊膚鹽選膚網製膚鬱憲淵醖鏇膚 (築繭淵壓觸壓餘鑰選鹽 )